HRT Financial’s Viking Therapeutics VKTX Stock Holding History

HRT Financial’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.96M	Buy	+60,300	New	+$1.94M	﹤0.01%	1627
2025 Q4	–	Sell	-154,100	Closed	-$4.05M	–	4114
2025 Q3	$4.05M	Buy	+154,100	New	+$4.6M	0.01%	784

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HRT Financial's VKTX Position: Q4 2025 in Review

HRT Financial sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 195,707 shares — an estimated $5.14M sold.

HRT Financial first reported a position in VKTX in Q4 2018 and held it in 14 quarters. The position peaked at $21M in Q2 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

HRT Financial reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 195,707 Viking Therapeutics shares in Q4 2025, an estimated $5.14M.
HRT Financial first reported a position in Viking Therapeutics in Q4 2018 and held it in 14 quarters.
HRT Financial's Viking Therapeutics position peaked at $21M in Q2 2024.
424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.